#United States #New York #Securities Fraud #Pomerantz LLP #Aldeyra

Investigation of Aldeyra Therapeutics, Inc.

In a significant development for shareholders, the Pomerantz Law Firm has initiated an investigation concerning potential securities fraud claims against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). This investigation was prompted by critical findings related to the company’s New Drug Application (NDA) for reproxalap, a drug intended for treating dry eye disease.

On April 3, 2025, Aldeyra announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA). Notably, the FDA’s letter did not highlight any manufacturing or safety concerns regarding reproxalap. However, it pointed out that the NDA submitted did not satisfactorily exhibit efficacy in adequately controlled studies for alleviating symptoms associated with dry eye. The FDA explicitly stated that at least one additional well-controlled study is necessary to validate a positive treatment effect.

The implications of this announcement were immediate and severe. Following the release of this news, Aldeyra’s stock plummeted by $3.90 per share, which translates to a staggering 73.31% decrease closing at $1.42 per share on the same day. Such volatility raises critical questions about the company's governance and the actions of its executives and board members.

Background on Pomerantz Law Firm

Pomerantz LLP is renowned for its efforts in corporate, securities, and antitrust class litigation. Established over 85 years ago by Abraham L. Pomerantz, a pivotal figure in the evolution of securities class actions, the firm maintains a legacy of fighting for victims of securities misconduct. It has successfully secured numerous multi-million dollar settlements in class action suits.

The current investigation into Aldeyra will focus on whether the company, along with its executives and directors, has engaged in deceptive practices that could potentially harm investors. Shareholders are encouraged to reach out to Danielle Peyton at Pomerantz for further information and inquiries pertaining to the class action.

For investors uncertain about their positions, this situation serves as a crucial reminder of the inherent risks in pharmaceutical investments, particularly concerning product approvals. With stringent oversight by the FDA, the approval process can be fraught with challenges, and this instance underscores the need for transparent and effective communication from companies to their stakeholders.

Next Steps for Investors

Shareholders who wish to understand their rights or who may have been adversely affected by Aldeyra’s stock performance should consider contacting legal counsel for advice. As this situation unfolds, ongoing communication from Pomerantz and further disclosures from Aldeyra will be essential for guiding investor decisions moving forward.

As always, monitoring the developments regarding Aldeyra Therapeutics will remain vital for current and prospective investors, especially those who are contemplating their engagement with the company amidst these legal inquiries.

For those interested, further information regarding the investigation and potential involvement can be located through Pomerantz's official communications.